Antitumor efficacy of BAFF-R targeting CAR T cells manufactured under clinic-ready conditions
Open Access
- 25 May 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cancer Immunology, Immunotherapy
- Vol. 69 (10), 2139-2145
- https://doi.org/10.1007/s00262-020-02614-8
Abstract
B-cell malignancies can potentially be cured by CD19 chimeric antigen receptor (CAR) T-cell therapy. Although clinical response rates can be up to 93% in acute lymphoblastic leukemia, treatment-related antigen loss and lack of therapeutic persistence contribute to disease relapse. These shortcomings of current CAR T-cell therapy indicate the need for biologically relevant target selection and for improving the efficacy and persistence of the CAR T cells, which we have addressed by developing a novel B-cell activating factor receptor (BAFF-R) CAR T-cell therapy with improved therapeutic persistence. BAFF-R is a B-cell survival receptor and highly expressed in B-cell malignancies. We developed a prototype CAR T cell that efficiently and specifically eliminated BAFF-R expressing human B-cell tumors in several xenogeneic mouse models, including models of CD19 antigen loss. We proceeded with translational development and validation of BAFF-R CAR T cells produced under current good manufacturing practices (cGMP). cGMP-grade BAFF-R CAR T cells underwent in vitro and in vivo validation in established models to confirm that the potency and efficacy of our original research modeling was replicated. Food and Drug Administration required release testing was performed to ensure our BAFF-R CAR T cells meet specifications for new drug products. Completing and exceeding these requirements, the data fully support the initiation of a first-in-human Phase 1 trial for BAFF-R-positive relapsed/refractory (r/r) B-ALL.Keywords
Funding Information
- Leukemia and Lymphoma Society (TRP 6540-18, MCL 7000-18)
- National Cancer Institute (SPORE 2P50CA107399, 1R21CA223141)
- U.S. Department of Defense (CA170783)
This publication has 15 references indexed in Scilit:
- Acute lymphoblastic leukemia: a comprehensive review and 2017 updateBlood Cancer Journal, 2017
- Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapiesJCI Insight, 2016
- Phase 1 studies of central memory–derived CD19 CAR T–cell therapy following autologous HSCT in patients with B-cell NHLBlood, 2016
- New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemiaCancer, 2015
- Improving the safety of cell therapy products by suicide gene transferFrontiers in Pharmacology, 2014
- Phenotypic and Functional Attributes of Lentivirus-modified CD19-specific Human CD8+ Central Memory T Cells Manufactured at Clinical ScaleJournal of Immunotherapy, 2012
- Engraftment of human central memory-derived effector CD8+ T cells in immunodeficient miceBlood, 2011
- The BLyS Family: Toward a Molecular Understanding of B Cell HomeostasisCell Biochemistry and Biophysics, 2008
- BAFF-R, the major B cell–activating factor receptor, is expressed on most mature B cells and B-cell lymphoproliferative disordersHuman Pathology, 2005
- Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcomeBlood, 2004